Neurogene Inc. — Director's Dealing 2020

Mar 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2020-03-16

Reporting Person: Ho Robert (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-16	Restricted Stock Units	$0.00	A	75000	Acquired		Common Stock (75000)	Direct
2020-03-16	Stock Option (Right to Buy)	$6.44	A	200000	Acquired	2030-03-16	Common Stock (200000)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F2: The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.

F4: The option vests as to 1/4 of the total shares on March 16, 2021, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.